The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients

The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients

Background: Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on de-escalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing fa...

Full description

Bibliographic Details
Main Authors: Miren Taberna, Montserrat Torres, María Alejo, Marisa Mena, Sara Tous, Sandra Marquez, Miquel A. Pavón, Xavier León, Jacinto García, Marta Guix, Rafael Hijano, Teresa Bonfill, Antón Aguilà, Alicia Lozano, Ricard Mesía, Laia Alemany, Ignacio G. Bravo
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Oncology
Subjects:
head and neck cancer
oropharyngeal cancer
Human Papillomavirus
HPV
EGFR
pEGFR
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00589/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00589/full

Similar Items